| (USD) | Mar 2024 | Q/Q |
|---|---|---|
| Revenue | 8.8B | -6% |
| Gross Profit | 7.1B | - |
| Cost Of Revenue | 1.7B | -6% |
| Operating Income | 2.5B | +1% |
| Operating Expenses | 4.6B | - |
| Net Income | 2.2B | +2% |
| R&D | - | - |
| G&A | 2B | +1% |
| Interest Expense | 179.6MM | +30% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in pa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
In this article, we discuss the 13 best stocks that will always grow. To skip the detailed analysis of the current economic landscape, go directly to the 5 Best Stocks That Will Always Grow. At the Federal Reserve’s May 1 meeting, Chairman Jerome Powell focused on the Fed’s dual mandate of promoting maximum employment and […]
In this article, we discuss the 10 companies to consider in the portfolio of Kevin O’Leary for 2024. If you want to skip our overview of O’Leary’s investment philosophy and learn about some more companies in his stock portfolio, go directly to Kevin O’Leary’s Stock Portfolio: 5 Stock Picks for 2024. Kevin O’Leary, affectionately known […]
Eli Lilly said on Tuesday a panel of independent U.S. FDA advisers will discuss its experimental Alzheimer's disease drug, donanemab, on June 10. Donanemab has faced two separate regulatory delays in the United States, while a similar therapy by Eisai and partner Biogen, called Leqembi, received the U.S. Food and Drug Administration's approval last year. Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of it...
Amazon stock climbs back near highs and is a mutual funds favorite. Shares gained more than 23% this year. Broadcom stock tests a key level.
After delaying an approval decision for Lilly’s donanemab, the agency now intends to hold an advisory committee meeting on June 10.
The company's payout is far from the only reason investors like the stock these days, but it certainly helps.
Eli Lilly ( NYSE:LLY ) First Quarter 2024 Results Key Financial Results Revenue: US$8.77b (up 26% from 1Q 2023). Net...